Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 17.33 is in line with its 1-year average of 18.80, near the low end of its 1-year range (16.96–20.60).
As of 2026-10-06T11:10:52.426Z.
Calculation as of: 2026-10-06T11:10:52.426Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3b719543d2ad964e34cebd38a4954272106044749b474b483c00e469aab85807
PE Ratio (17.33) = Close Price ($228.03) / Diluted TTM EPS ($13.16)
PE RATIO
17.33
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.73
median of 116 covered companies
CURRENT VS SECTOR MEDIAN
-32.66%
vs the sector median at left
Market Cap
$14.97B
PE Ratio
N/A
TTM Avg
224.88
3Y Avg
91.13
5Y Avg
72.06
Market Cap
$13.19B
PE Ratio
290.55
TTM Avg
139.19
3Y Avg
74.59
5Y Avg
55.44
Market Cap
$12.89B
PE Ratio
39.51
TTM Avg
24.39
3Y Avg
28.29
5Y Avg
40.31
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 17.33 | N/A | N/A | N/A |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A | N/A | N/A | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 18.45 | 17.38 | 27.68 | 29.19 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | N/A | 224.88 | 91.13 | 72.06 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 290.55 | 139.19 | 74.59 | 55.44 |
| Solventum Corporation (SOLV)vs › | $15.24B | 10.75 | 11.49 | 16.23 | 16.23 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | N/A | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 39.51 | 24.39 | 28.29 | 40.31 |
| Baxter International Inc. (BAX)vs › | $12.52B | N/A | 44.52 | 34.38 | 37.41 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 77.91 | 74.60 | 221.06 | 402.75 |
At 17.3, P/E is below its 1-year median — higher than 19% of readings in its 1-year history.
1-year low
17.0
median
18.9
1-year high
20.6
Trailing P/E
17.3
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 17.33 |
| 2026-10-02 | 17.32 |
| 2026-10-01 | 17.27 |
| 2026-09-30 | 17.31 |
| 2026-09-29 | 17.33 |
| 2026-09-28 | 17.48 |
| 2026-09-25 | 17.14 |
| 2026-09-24 | 17.53 |
| 2026-09-23 | 16.96 |
| 2026-09-22 | 18.05 |
| 2026-09-21 | 18.05 |
| 2026-09-18 | 17.99 |
| 2026-09-17 | 18.16 |
| 2026-09-16 | 18.82 |
| 2026-09-15 | 18.22 |
| 2026-09-14 | 20.13 |
| 2026-09-11 | 20.03 |
| 2026-09-10 | 19.85 |
| 2026-09-09 | 19.82 |
| 2026-09-08 | 20.52 |
| 2026-09-04 | 20.56 |
| 2026-09-03 | 20.60 |
| 2026-09-02 | 20.31 |
| 2026-09-01 | 19.78 |
| 2026-08-31 | 19.99 |
| 2026-08-28 | 18.84 |
| 2026-08-27 | 18.95 |
| 2026-08-26 | 19.02 |
| 2026-08-25 | 19.22 |
| 2026-08-24 | 19.15 |
| 2026-08-21 | 19.25 |
| 2026-08-20 | 19.36 |
| 2026-08-19 | 19.73 |
| 2026-08-18 | 18.91 |
| 2026-08-17 | 18.80 |
| 2026-08-14 | 18.88 |